Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blin...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/11645 |
| Aporte de: |
| id |
I33-R139123456789-11645 |
|---|---|
| record_format |
dspace |
| institution |
Universidad Católica Argentina |
| institution_str |
I-33 |
| repository_str |
R-139 |
| collection |
Repositorio Institucional de la Universidad Católica Argentina (UCA) |
| language |
Inglés |
| topic |
NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA |
| spellingShingle |
NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert-Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
| topic_facet |
NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA |
| description |
Abstract: Background: There are no effective treatments for multiple system atrophy (MSA).
Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score.
Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo).
Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. |
| format |
Artículo |
| author |
Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert-Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. |
| author_facet |
Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert-Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. |
| author_sort |
Rascol, Olivier |
| title |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
| title_short |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
| title_full |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
| title_fullStr |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
| title_full_unstemmed |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
| title_sort |
fluoxetine for the symptomatic treatment of multiple system atrophy : the msa-fluo trial |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://repositorio.uca.edu.ar/handle/123456789/11645 |
| work_keys_str_mv |
AT rascololivier fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT cochendecockvalerie fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT pavyletraonanne fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT foubertsamieralexandra fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT thalamasclaire fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT sommetagnes fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT rousseauvanessa fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT perezlloretsantiago fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT fabbrimargherita fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT azulayjeanphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT corvoljeanchristophe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT couratierphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT damierphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT defebvreluc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT duriffranck fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT genychristian fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT houetojeanluc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT remyphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT tranchantchristine fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT verinmarc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT tisonfrancois fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT meissnerwassiliosg fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial |
| bdutipo_str |
Repositorios |
| _version_ |
1764820525171867648 |